These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 20142042)
1. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Smith KT; Martin-Brown SA; Florens L; Washburn MP; Workman JL Chem Biol; 2010 Jan; 17(1):65-74. PubMed ID: 20142042 [TBL] [Abstract][Full Text] [Related]
2. Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network. Sardiu ME; Smith KT; Groppe BD; Gilmore JM; Saraf A; Egidy R; Peak A; Seidel CW; Florens L; Workman JL; Washburn MP Mol Cell Proteomics; 2014 Nov; 13(11):3114-25. PubMed ID: 25073741 [TBL] [Abstract][Full Text] [Related]
3. Synergistic antineoplastic effect of DLC1 tumor suppressor protein and histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), on prostate and liver cancer cells: perspectives for therapeutics. Zhou X; Yang XY; Popescu NC Int J Oncol; 2010 Apr; 36(4):999-1005. PubMed ID: 20198346 [TBL] [Abstract][Full Text] [Related]
4. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid. Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198 [TBL] [Abstract][Full Text] [Related]
5. SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors. Desai D; Salli U; Vrana KE; Amin S Bioorg Med Chem Lett; 2010 Mar; 20(6):2044-7. PubMed ID: 20167479 [TBL] [Abstract][Full Text] [Related]
6. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity. Negmeldin AT; Knoff JR; Pflum MKH Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330 [TBL] [Abstract][Full Text] [Related]
8. Phosphorus containing analogues of SAHA as inhibitors of HDACs. Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA. Cheng HT; Hung WC Oncol Rep; 2013 Aug; 30(2):961-7. PubMed ID: 23754070 [TBL] [Abstract][Full Text] [Related]
10. Human family with sequence similarity 60 member A (FAM60A) protein: a new subunit of the Sin3 deacetylase complex. Smith KT; Sardiu ME; Martin-Brown SA; Seidel C; Mushegian A; Egidy R; Florens L; Washburn MP; Workman JL Mol Cell Proteomics; 2012 Dec; 11(12):1815-28. PubMed ID: 22984288 [TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. You BR; Han BR; Park WH Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148 [TBL] [Abstract][Full Text] [Related]
12. Expression of the Neural REST/NRSF-SIN3 Transcriptional Corepressor Complex as a Target for Small-Molecule Inhibitors. Jayaprakash S; Le LTM; Sander B; Golas MM Mol Biotechnol; 2021 Jan; 63(1):53-62. PubMed ID: 33130996 [TBL] [Abstract][Full Text] [Related]
13. Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate. Sekhavat A; Sun JM; Davie JR Biochem Cell Biol; 2007 Dec; 85(6):751-8. PubMed ID: 18059533 [TBL] [Abstract][Full Text] [Related]
14. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. Negmeldin AT; Pflum MKH Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Gui CY; Ngo L; Xu WS; Richon VM; Marks PA Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1241-6. PubMed ID: 14734806 [TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Dokmanovic M; Perez G; Xu W; Ngo L; Clarke C; Parmigiani RB; Marks PA Mol Cancer Ther; 2007 Sep; 6(9):2525-34. PubMed ID: 17876049 [TBL] [Abstract][Full Text] [Related]
17. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation. Hutt DM; Roth DM; Marchal C; Bouchecareilh M Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814 [TBL] [Abstract][Full Text] [Related]
18. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Marks PA Cell Cycle; 2004 May; 3(5):534-5. PubMed ID: 15020838 [TBL] [Abstract][Full Text] [Related]
19. Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Kortenhorst MS; Wissing MD; Rodríguez R; Kachhap SK; Jans JJ; Van der Groep P; Verheul HM; Gupta A; Aiyetan PO; van der Wall E; Carducci MA; Van Diest PJ; Marchionni L Epigenetics; 2013 Sep; 8(9):907-20. PubMed ID: 23880963 [TBL] [Abstract][Full Text] [Related]
20. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. Codd R; Braich N; Liu J; Soe CZ; Pakchung AA Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]